Clinical trial

Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)

NCT02979821

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2016-10-01

PhasePHASE2

Study timeline

Study start (actual)2016-10-01Date precision: month

Registry last updated2018-05-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

HER2 Gene Mutationunresolved

Adenocarcinoma Lung Stage IVunresolved

Interventions

Sponsors & collaborators

Korean Association for the Study of Targeted Therapylead sponsor

Konkuk University Medical Centercollaborator

Kyungpook National University Hospitalcollaborator

Kosin University Gospel Hospitalcollaborator

Chonnam National University Hospitalcollaborator

Chungnam National University Hospitalcollaborator

Mapped research locations

SeoulSouth Korea1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02979821 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.